and endoscopic response at several possible eosinophil count cutpoints (eos/hpf). Predictors of response were also assessed.

RESULTS: Of 224 treatments in 199 patients, 76% were associated with symptomatic improvement, 68% with endoscopic improvement, and 60% with both. Of treatments that resulted in a post-treatment count of <15 eos/hpf, 90% were associated with an endoscopic response, 88% with a symptomatic response, and 81% with both symptomatic and endoscopic responses. Using a <15 eos/hpf threshold, the area under the curves (AUCs) were 0.70, 0.78, and 0.75 for symptomatic, endoscopic, and symptomatic/endoscopic responses, respectively. Lower histologic cut-points did not result in a substantial gain in response, but decreased the AUC.

CONCLUSION: In this large cohort of EoE patients, rates of symptomatic and endoscopic improvement were generally associated with histologic improvement. A histologic cutoff for treatment response of <15 eos/hpf may balance clinical outcomes and test performance.

© 2015 ACT. All rights reserved.

Key words: Eosinophilic esophagitis; Treatment; Cutpoint; Corticosteroids; Dietary therapy

W. Asher Wolf, Cary C. Cotton, Daniel J. Green, Julia T. Hughes, John T. Woosley, Nicholas J. Shaheen, Evan S. Dellon

ABSTRACT

AIM: No consensus exists on the definition of successful treatment in eosinophilic esophagitis (EoE). The aim of this study was to identify the optimal histologic cutpoint to define successful treatment of EoE by assessing rates of symptomatic and endoscopic improvement.

MATERIALS AND METHODS: We performed a retrospective cohort study utilizing the University of North Carolina EoE Clinicopathologic Database between 2006 and 2013. Rates of symptomatic and endoscopic improvement were determined, as were post-treatment eosinophil counts. The area under the receiver operator characteristic curve (AUC) was calculated for symptomatic and endoscopic response at several possible eosinophil count cutpoints (eos/hpf). Predictors of response were also assessed.

RESULTS: Of 224 treatments in 199 patients, 76% were associated with symptomatic improvement, 68% with endoscopic improvement, and 60% with both. Of treatments that resulted in a post-treatment count of <15 eos/hpf, 90% were associated with an endoscopic response, 88% with a symptomatic response, and 81% with both symptomatic and endoscopic responses. Using a <15 eos/hpf threshold, the area under the curves (AUCs) were 0.70, 0.78, and 0.75 for symptomatic, endoscopic, and symptomatic/endoscopic responses, respectively. Lower histologic cut-points did not result in a substantial gain in response, but decreased the AUC.

CONCLUSION: In this large cohort of EoE patients, rates of symptomatic and endoscopic improvement were generally associated with histologic improvement. A histologic cutoff for treatment response of <15 eos/hpf may balance clinical outcomes and test performance.

© 2015 ACT. All rights reserved.

Key words: Eosinophilic esophagitis; Treatment; Cutpoint; Corticosteroids; Dietary therapy

Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, Shaheen NJ, Dellon ES. Evaluation of Histologic Cutpoints for Treatment Response in Eosinophilic Esophagitis. Journal of Gastroenterology and Hepatology Research 2015; 4(10): 1780-1787 Available from: URL: http://www.ghrnet.org/index.php/joghr/article/view/1337

INTRODUCTION

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disorder of the esophagus defined by ≥15 eosinophils per high powered field (eos/hpf) on esophageal biopsy accompanied by esophageal dysfunction in the absence of competing causes of
Patients, data sources, and outcomes

We performed a retrospective cohort analysis of patients at University of North Carolina (UNC) Hospitals from 2006-2013. Patients of any age with EoE were identified from the UNC EoE Clinico-pathologic Database[12,13]. For inclusion, patients had to have EoE by consensus guidelines, including failure to respond to a PPI trial[14,15]; undergo treatment with swallowed topical corticosteroids (tCS) or dietary therapy; and have a follow up endoscopy with biopsy. Treatment with tCS consisted of either budesonide (0.5-1 mg twice daily, depending on patient age)[14,15] or fluticasone (440-880 mcg twice daily, depending on patient age)[16-18]. Dietary therapy consisted of six food elimination diets or targeted elimination diets[19-21]. Patients were treated with either tCS or dietary elimination for approximately 8 weeks prior to reassessment with esophagogastroduodenoscopy (EGD). For patients undergoing serial therapeutic trials of pharmacologic treatment modalities (for example fluticasone followed by budesonide), the results from the trial resulting in the lowest post-treatment eosinophil count were used for analysis. For patients undergoing sequential trials of dietary and steroid therapy (for example, dietary therapy after steroid therapy had failed), each therapeutic outcome was included. When a patient had outcomes for both dietary and steroid therapy, the eosinophil count from the diagnostic pre-treatment EGD was used to determine the percentage change in eosinophils.

Data were abstracted from the UNC electronic medical record. Using standardized data collection tools, we recorded patient demographics, symptoms, comorbidities, baseline and follow-up endoscopy findings, baseline and follow-up eosinophil counts on esophageal biopsy, and therapeutic regimen. Pre- and post-treatment eosinophil counts were recorded as the maximum number of eosinophils per high-power field (eos/hpf; hpf size = 0.24mm²) from pathologist review. Treatment outcomes were defined as follows: symptom response (dichotomous patient-reported subjective improvement [yes/no]); endoscopic response (dichotomous endoscopist-reported assessment of improvement [yes/no]), and both symptom and endoscopic response.

METHODS

Outcomes and Determination of Histologic Cut-Points

Of 224 sets of treatment outcomes, 125 (56%) resulted in post-treatment eosinophil counts meeting a response threshold of <15 eos/hpf (Figure 1a), while only 64 (29%) met the most stringent criteria of 0 eos/hpf (Table 2). There were 154 (69%) treatment courses that decreased eosinophil counts from baseline by ≥50% (Figure 1b), while 85 (38%) had a decrease in counts by ≥97.5%. Of 223 treatment courses with endoscopist-reported global assessment, 152 (68%) demonstrated improvement. Among the 193 treatment courses with symptom outcome data, 146 (76%) reported improvement. Of 192 outcomes where both symptoms and endoscopic outcomes were reported, 146 (76%) reported improvement. For evaluation of treatment outcomes, a per-treatment analysis was performed, allowing inclusion of both outcomes for patients who underwent separate courses of steroid and dietary therapy.

RESULTS

Concordance of Symptomatic, Endoscopic, and Histologic Outcomes and Determination of Histologic Cut-Points

We identified 199 patients with EoE meeting inclusion criteria. The mean age was 27, and they were predominately white (84%), male (68%), and had a history of atopic disease (52%) (Table 1). Eighty-three percent were adults (≥18 years old) at the time of diagnosis. The predominant baseline symptom was dysphagia (72%). Baseline endoscopies demonstrated features typical of EoE with furrows (56%), rings (49%), decreased vascularity (32%), and narrowing (20%). Twenty-seven percent required dilation at the time of diagnosis. Mean baseline eosinophil count was 74 ± 56 eos/hpf.

The majority of patients received tCS therapy alone (n=165, 83%), while a small number were prescribed dietary elimination (n=9, 5%). The remainder underwent separate trials of each therapy (n= 25, 13%), resulting in a total of 224 treatment outcomes that were used for the per-treatment analyses.

Data Analysis

All data were analyzed using SAS version 9.3 (Cary, NC). Bivariate analyses were performed with chi-square testing for categorical variables. Because all continuous variables were not normally distributed, the Wilcoxon two-tailed t approximation (rank-sum) was used for evaluation of treatment outcomes, a per-treatment analysis was performed, allowing inclusion of both outcomes for patients who underwent separate courses of steroid and dietary therapy. Receiver operator characteristic (ROC) curves were generated and the area under the curve (AUC) was calculated for multiple values of the post-treatment eosinophil count (eos/hpf) as well as for the percentage change in the eosinophil count compared to baseline. Because dilation can produce symptomatic improvement without endoscopic or histologic improvement, we conducted a subgroup analysis among patients not undergoing dilation at baseline (prior to treatment) to evaluate outcomes. For patients treated with tCS, those with concordant symptomatic, endoscopic, and histologic response (<15 eos/hpf) were compared to those without using a bivariate analysis. For inclusion in this portion of the analysis, patients had to have recorded symptomatic and endoscopic response variables and pre- and post-treatment eosinophil counts. A logistic regression model was constructed to assess predictors of concordant response by including all variables significant at the p=0.2 level and then reducing until all factors were significant at the p=0.05 level. This study was approved by the UNC Institutional Review Board.

Data Analysis

All data were analyzed using SAS version 9.3 (Cary, NC). Bivariate analyses were performed with chi-square testing for categorical variables. Because all continuous variables were not normally distributed, the Wilcoxon two-tailed t approximation (rank-sum) was used.
eosinophil counts, regardless of whether there was an associated symptom response or not (Figure 1c).

Among patients achieving <15 eos/hpf, 90% had endoscopic response, 88% had symptomatic response, and 81% had both symptomatic and endoscopic response. Using a cutoff of <15 eos/hpf, the AUCs for symptomatic, endoscopic and concordant responses were 0.70, 0.78, and 0.75, respectively (Table 2; Figure 2a-c). At a cutoff of 0 eos/hpf, 92% had EGD response, 93% had symptomatic response, and 85% had both. Here, the AUCs for symptomatic, endoscopic, and concordant responses were 0.64, 0.66, and 0.65, respectively. Excluding patients who had undergone dilation did not alter rates of symptomatic, endoscopic or concordant response (data not shown). On logistic regression, a post-treatment eosinophil count decrease of 1 eos/hpf increased the odds of symptomatic response by 2% [OR 1.02 (1.01-1.02)], endoscopic response by 4% [OR 1.04 (1.03-1.06)], and concordant endoscopic and symptomatic response by 5% [OR 1.05 (1.03-1.07)] (Figure 3a-c).

Results were similar using a percentage change in the post-treatment eosinophil count. For example, a decrease of 50% was associated with both an endoscopic and a symptom response rate of 84%, and concordant symptomatic and endoscopic response in 75%. Endoscopic response was associated with large percentage decreases in eos regardless of whether there was a symptomatic response, while symptomatic response in the absence of an endoscopic response was not associated with a clear pattern (Figure 1d). Using a 50% decrease in post-treatment eosinophil count, the AUCs for symptomatic, endoscopic, and concordant response were 0.66, 0.76, and 0.72, respectively (Figure 2a-c). For a decrease of 97.5%, the symptomatic response rate was 89%, the endoscopic response rate was 93%, and concordant response occurred in 84%. Here, the AUCs for symptomatic, endoscopic, and concordant responses were 0.64, 0.71, and 0.69, respectively. Excluding patients who had undergone dilation did not alter rates of symptomatic, endoscopic or concordant response (data not shown). On logistic regression, a post-treatment decrease in the eosinophil count of 1% increased the odds of symptomatic response by 1% [OR 1.01 (1.01-1.01)], endoscopic response by 2% [OR 1.02 (1.01-1.02)], and concordant endoscopic and symptomatic response by 2% [OR 1.02 (1.01-1.02)] (Figure 3d-f).

Factors Associated with Concordant Outcomes in Patients Treated with tCS

To assess factors associated with concordant symptomatic, endoscopic, and histologic outcomes, we compared patients treated with tCS who had <15 eos/hpf on follow up biopsy accompanied by symptomatic and endoscopic improvement (n=77, 44%) to patients who did not achieve improvement in all three categories (n=98 56%). Patients with concordant results did not differ from those with discordant or non-response on demographic features, and had similar baseline eosinophil counts and rates of atopy and food allergies (Table 3). Patients with concordant response were more likely to present with abdominal pain (24% vs 11, p = 0.03) and nausea (16% vs 6, p = 0.04). Endoscopy of patients with concordant response was less likely to show narrowing (13% vs 26, p = 0.04) or require dilation (19% vs 34, p = 0.03). On multivariate logistic regression, non-white race [OR 2.6 (1.1-6.4)] and the absence of dilation [OR 2.5 (1.2-5.1)] predicted concordant response. After adjustment for atopic status, baseline eos/hpf, and age, only absence of dilation [OR 3.1 (1.4-6.6)] was a significant predictor of concordance.

Table 1 Demographics and Baseline Characteristics (n = 199)

| Age, mean years ± SD | 27 ± 18 |
|----------------------|---------|
| White Race, n (%)    | 166 (84) |
| Male, n (%)          | 136 (69) |
| Adult > 18 years, n (%) | 125 (63) |
| Atopic Disease, n (%) | 102 (52) |
| Asthma, n (%)        | 50 (25)  |
| Food Allergy, n (%)  | 65 (36)  |
| Baseline eosinophil counts (eos/hpf, mean ± SD) | 74 ± 56 |

Table 2 Treatment Response, ROC-derived AUC, and Outcome Concordance by Histologic Response Threshold

| Eosinophil Cutoff | Histologic Response N = 224, n (%) | Frequency at Given Histologic Threshold (%) | AUC [95% CI] | Frequency at Given Histologic Threshold (%) | AUC [95% CI] | Frequency at Given Histologic Threshold (%) | AUC [95% CI] |
|-------------------|------------------------------------|---------------------------------------------|-------------|---------------------------------------------|-------------|---------------------------------------------|-------------|
| <50 eos/hpf       | 144 (64)                           | 90                                          | 0.62 [0.60, 0.65] | 87                                          | 0.70 [0.62, 0.77] | 79                                          | 0.77 [0.70, 0.85] |
| <20 eos/hpf       | 132 (59)                           | 90                                          | 0.64 [0.62, 0.67] | 88                                          | 0.70 [0.63, 0.78] | 81                                          | 0.77 [0.70, 0.85] |
| <10 eos/hpf       | 115 (51)                           | 91                                          | 0.70 [0.68, 0.73] | 88                                          | 0.70 [0.62, 0.77] | 81                                          | 0.75 [0.69, 0.81] |
| <5 eos/hpf        | 106 (47)                           | 90                                          | 0.76 [0.69, 0.80] | 87                                          | 0.66 [0.59, 0.74] | 81                                          | 0.73 [0.66, 0.79] |
| <3 eos/hpf        | 88 (39)                            | 92                                          | 0.71 [0.66, 0.77] | 86                                          | 0.64 [0.56, 0.71] | 79                                          | 0.69 [0.63, 0.76] |
| 0 eos/hpf         | 84 (38)                            | 92                                          | 0.70 [0.65, 0.75] | 91                                          | 0.66 [0.60, 0.72] | 84                                          | 0.70 [0.63, 0.76] |
| 0 eos/hpf         | 64 (29)                            | 92                                          | 0.66 [0.61, 0.70] | 93                                          | 0.64 [0.58, 0.69] | 85                                          | 0.65 [0.60, 0.71] |

Eosinophil Count Percentage Decrease from Pre- to Post-Treatment

-5% 154 (69) 84 0.76 [0.69, 0.82] 84 0.66 [0.58, 0.74] 75 0.72 [0.66, 0.79] 
-7% 134 (60) 90 0.80 [0.75, 0.86] 88 0.71 [0.63, 0.79] 80 0.76 [0.70, 0.82] 
-9% 105 (47) 91 0.75 [0.69, 0.80] 87 0.65 [0.57, 0.72] 80 0.70 [0.64, 0.77] 
-9% 95 (42) 93 0.74 [0.68, 0.79] 89 0.65 [0.58, 0.72] 83 0.70 [0.64, 0.76] 
-9% 85 (38) 93 0.71 [0.66, 0.77] 89 0.64 [0.57, 0.71] 84 0.69 [0.63, 0.75]
Wolf WA et al. Histologic treatment response cutpoints for EoE

Figure 1 Histogram of proportion of patients by eosinophil count (eos/hpf) after treatment (1a) and the percentage change in eosinophil count after treatment (1b). Histogram of post-treatment eosinophil counts (eos/hpf) stratified by endoscopic and symptom response (1c) and of the percentage change in eosinophil counts after treatment, also stratified by endoscopic and symptom response (1d).

Figure 2 ROC curves comparing the post-treatment eosinophil count (eos/hpf) and percentage change in eosinophil count after treatment as a test for symptom response (2a), endoscopic response (2b), and concurrent endoscopic and symptom response (2c).
DISCUSSION

Limited data exist describing the relationship of symptomatic, endoscopic, and histologic outcomes in EoE, and no consensus exists on the optimal post-treatment histologic cut-points for eosinophil counts. In this study of a large cohort of EoE patients treated with tCS and diet, we examined the frequency of concordant improvement in these three clinical outcomes and explored the implications of using different eosinophil counts as the threshold for successfully treated disease. Importantly, we found that among patients achieving histologic response, concordant response was relatively frequent, with over 80% of those with <15 eos/hpf also achieving symptomatic and endoscopic response.

Previous studies have not shown consistent results with respect to concordance of histologic, endoscopic, and symptomatic outcomes. For example, two studies by the same group had conflicting results. In one, a symptom score showed dissociation with histologic severity as measured by the eosinophil count in children with EoE[22]. In the other, there was a correlation between the presence of dysphagia and increasing eosinophil counts[23]. In clinical trials, however, this inconsistency may be attributable to variable histologic endpoints. For example, among studies where treatment achieved mean
c eosinophil counts of <15 eos/hpf (regardless of the stated primary histologic outcome), concordant symptomatic and endoscopic response was actually common (though some trials did not include both outcomes)[9-11,29]. Only one trial achieved <15 eos/hpf without demonstrating improvement in symptoms or endoscopy, though there was a trend towards both symptomatic and endoscopic improvement that may not have reached significance due to sample size[27]. In contrast, trials that failed to lower eosinophil counts to <15, even those demonstrating statistically significant decreases in eos/hpf, had inconsistent symptomatic and endoscopic outcomes[4,24,25].

We also explored factors which were associated with concordant outcomes in steroid therapy, but found that few clinical, endoscopic, or histologic factors predicted concordant response. While several factors appeared to differ on bivariate analysis, only the lack of dilation at baseline remained significant after multivariate logistic regression. Our previous research has indicated that the need for dilation is a marker of refractory disease[26], making histologic response less likely in this population and potentially contributing to a decrease in concordant response. The need for dilation may also represent a more advanced or treatment-resistant clinical phenotype, which could also contribute to discordant responses.

If a histologic response outcome were to be used as a measure of treatment efficacy, based on our data we favor using the absolute eosinophil count over the percentage change. This is because the ongoing presence of large numbers of eosinophils, which would occur in patients with high baseline counts treated to an endpoint of 50 or 75% reduction, may result in ongoing risk for fibrotic remodeling of the esophagus based on new natural history data[27,28]. Based on exploration of our data, a threshold of <15 eos/hpf could be considered a reasonable threshold. Our analysis demonstrates that the rate of endoscopic and symptomatic response increases with decreasing eosinophil counts. Notably, though, pushing the response threshold lower than <15 eos/hpf results in only small further gains in symptom and endoscopic improvement. For example, by decreasing the eosinophil cutoff from <15 eos/hpf to 0, the symptomatic response rate increases 5%, the endoscopic response rate 2%, and the concordant response rate 4%. These improvements are offset by a decline in the test performance which is substantial.

This study has several potential limitations. First, it is retrospective, resulting in the possibility of non-differential classification bias. In addition, we rely on non-validated, binary (yes/no) measures of symptom and endoscopic response. Though a necessity due to the retrospective design, we are unable to assess the specific components of patients’ symptoms and endoscopy which may (or may not) have responded to therapy. We have utilized this method because no validated measures of symptomatic or endoscopic response existed during the study time frame, we have employed similar measures in other studies[18,26], and it has the benefit of reflecting the patient’s global status – did they feel better and did their endoscopy look better? We acknowledge that validated symptom and endoscopic assessments for evaluating EoE have recently been published[9-11,29] and these should be applied in future prospective studies to help answer this question more definitively. However, such symptom metrics may not come to be used in routine practice, and some clinicians may continue to use a clinical outcome measure more akin to what we employed during this study. We also note that our outcomes are assessed only after an initial 8 week treatment course. Therefore, we are unable to comment on whether this histologic threshold might decrease long-term complications such as fibrosis and strictures of the esophagus, important issues that would need to be assessed in long-term prospective studies.

This study also has multiple strengths. This is one of the largest cohorts reported to date with follow-up data on patients treated both with tCS and dietary therapy. This allowed both a per-patient, and per-treatment analysis. Additionally, because these results were found outside of a clinical trial, we believe they represent “real-world” response rates which could be typical of clinical practice, giving them broad applicability. The analyses linking specific histologic treatment outcomes to symptomatic and endoscopic responses are also unique in the EoE literature.

In conclusion, we have identified a high degree of concordance between symptomatic endoscopic improvement in EoE patients who also have histologic response to treatment, though note that many patients still fail to respond to treatment. In exploring potential histologic outcome thresholds, we favor an eosinophil cut-point of <15 eos/hpf as this optimizes the tradeoffs between improved outcomes and losses in test performance. It also provides conceptual symmetry, mirroring the current diagnostic threshold of ≥15 eos/hpf, which has recently been supported by empiric data[20]. While these findings should be interpreted in the context of a retrospective study, they provide a starting point for further investigations where the merits of this response threshold in a prospectively followed cohort of EoE, as well as the long-term outcomes and treatment options for patients failing to achieving this <15 eos/hpf, can be assessed.

Table 3 Factors Associated with Concordant Histologic, Endoscopic, and Symptom Response to Steroid Therapy

| Factor                        | Discordant (n = 98) | Concordant (n = 77) | p-value |
|-------------------------------|---------------------|---------------------|---------|
| Age, mean ± SD               | 24 ± 17             | 29 ± 18             | 0.06    |
| White Race, n (%)            | 77 (79)             | 69 (90)             | 0.05    |
| Male, n (%)                  | 71 (72)             | 51 (66)             | 0.37    |
| Adult ≥ 18 years, n (%)      | 60 (61)             | 65 (80)             | 0.81    |
| Atopic Disease, n (%)        | 47 (48)             | 38 (49)             | 0.96    |
| Asthma, n (%)                | 26 (27)             | 19 (25)             | 0.75    |
| Food Allergy, n (%)          | 25 (27)             | 24 (31)             | 0.34    |
| Baseline maximum eosinophil count (eos/hpf, mean ± SD) | 75 ± 63             | 78 ± 62             | 0.35    |

Baseline symptoms

- Abdominal Pain, n (%) 11 (11) 18 (24) 0.03
- Chest Pain, n (%) 8 (8) 13 (17) 0.08
- Dysphagia, n (%) 70 (72) 55 (72) 0.94
- Heartburn, n (%) 41 (43) 26 (34) 0.26
- Nausea, n (%) 6 (6) 12 (16) 0.04
- Vomiting, n (%) 25 (26) 22 (29) 0.67
- Food Impaction, n (%) 30 (31) 26 (37) 0.44

Baseline EGD Findings

- Normal, n (%) 7 (7) 6 (8) 0.85
- Rings, n (%) 52 (53) 37 (49) 0.57
- Narrowing, n (%) 25 (26) 10 (13) 0.04
- Stricture, n (%) 23 (23) 15 (20) 0.55
- Furrrows, n (%) 38 (39) 41 (54) 0.49
- White Flakes, n (%) 33 (34) 22 (29) 0.51
- Decreased Vascularity, n (%) 33 (34) 23 (30) 0.63
- Crepe Paper, n (%) 8 (8) 4 (5) 0.45
- Histal Hernia, n (%) 9 (9) 6 (8) 0.74
- Dilation Performed, n (%) 33 (34) 14 (19) 0.03

Steroid Therapy Details

- Budesonide, n (%) 69 (70) 60 (78) 0.26
- Fluticasone, n (%) 29 (30) 17 (22) 0.72
- Budesonide dose, mean mcg ± SD 1614 ± 673 1792 ± 709 0.18
- Fluticasone dose, mean mcg ± SD 1244 ± 620 1310 ± 579 0.71

**ACKNOWLEDGMENTS**

**Financial Support:** This research was supported, in part, by NIH awards T32DK007634 (WAW), P30DK034987 (WAW), K24DK100548 (NJS), and K23DK090073 (ESD).

**Specific author contributions:** Wolf: Manuscript drafting, data
analysis/interpretation; critical revision; Cotton: Data extraction, critical revision; Green: Data extraction, critical revision; Hughes: Data extraction, critical revision; Woosley: Pathology supervision, critical revision; Shaheen: Data interpretation, critical revision; Dellon: Project conception, supervision; data analysis/interpretation, critical revision.

Competing interests: Dr. Dellon has received research funding from AstraZeneca, Meritage, Receptos, and Regeneron, an educational grant from Diagnovus, and is a consultant for Aptalis, Novartis, Receptos, Regeneron, and Roche. None of the other authors have any relevant conflicts of interest to disclose.

REFERENCES

1. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassell E, Straumann A, Rothenberg ME. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133: 1342-1363
2. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Chehade M, Collins MH, Dellon ES, Dohil R, Fark GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, Shaheen NJ, Sicherer SH, Spechler S, Spiegel JM, Straumann A, Wershil BK, Rothenberg ME, Avees SS. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3-20.e6
3. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras C, Katzka DA. ACG Clinical Guideline: Evidence based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis. Am J Gastroenterol 2013; 108: 679-692
4. Dellon ES, Aderoju A, Woosley JT, Sandler RS, Shaheen NJ, Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol 2007; 102: 2300-2313
5. Sperry SL, Shaheen NJ, Dellon ES. Toward uniformity in the diagnosis of eosinophilic esophagitis (EoE): the effect of guidelines on variability of diagnostic criteria for EoE. Am J Gastroenterol 2011; 106: 824-32; quiz 833
6. Hirano I. Editorial: Should patients with suspected eosinophilic esophagitis undergo a therapeutic trial of proton pump inhibition? Am J Gastroenterol 2013; 108: 373-375
7. Hirano I. Therapeutic End Points in Eosinophilic Esophagitis: Is Elimination of Esophageal Eosinophils Enough? Clin Gastroenterol Hepatol 2012; 10: 750-752
8. Gonsalves N, Doerfler B, Schwartz S, Yang GY, Zalewski A, Amsden K, Mughal S, Manuel-Rubio M, Melin-Aldana H, Wershil BK, Hirano I, Kangwalla AF. Prospective trial of four food elimination diets demonstrates comparable effectiveness in the treatment of adult and pediatric eosinophilic esophagitis. Gastroenterology 2013; 144 (Suppl 1): S-154 (AB 877)
9. Schoepfer AM, Straumann A, Panczik R, Coslovsky M, Kuehni CE, Maurer E, Haas NA, Romero Y, Hirano I, Alexander JA, Gonsalves N, Furuta GT, Dellon ES, Leung J, Collins MH, Bussmann C, Netzer P, Gupta SK, Avees SS, Chehade M, Moawad FJ, Enders FT, Yost KJ, Taft TH, Kern E, Zwahlen M, Sfornoeva E. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology 2014; 147: 1255-66.e21
10. Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013; 62: 489-495
11. Dellon ES, Irani AM, Hill MR, Hirano I. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. Aliment Pharmacol Ther 2013; 38: 634-642
12. Dellon ES, Gibbs WB, Fritchke KJ, Rubinas TC, Wilson LA, Woosley JT, Shaheen NJ. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009; 7: 1305-1313
13. Dellon ES, Chen X, Miller CR, Woosley JT, Shaheen NJ. Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. Am J Gastroenterol 2012; 107: 1503-1511
14. Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM, Ivanovic M, Chau A, Woosley JT, Madanick RD, Orlando RC, Shaheen NJ. Viscous Topical Is More Effective than Nebulized Steroid Therapy for Patients with Eosinophilic Esophagitis. Gastroenterology 2012; 143: 321-324.e1
15. Dohil R, Newbury R, Fox L, Bastian J, Avees S. Oral Viscous Budesonide Is Effective in Children With Eosinophilic Esophagitis in a Randomized, Placebo-controlled Trial. Gastroenterology 2010; 139: 418-429
16. Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, Akers R, Cohen MB, Collins MH, Assa’aad AH, Avees SS, Putnam PE, Rothenberg ME. A randomized, double blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006; 131: 1381-1391
17. Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephard GM, Kita H, Kryzer LA, Romero Y, Smyrk TC, Talley NJ. Swallowed Fluticasone Improves Histology but Not Symptomatic Responses of Adults with Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2012; 10: 742-9.e1
18. Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2015; 13: 66-76.e3
19. Wolf WA, Jerath MR, Sperry SL, Shaheen NJ, Dellon ES. Dietary Elimination Therapy Is an Effective Option for Adults With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2014; 12: 1272-1279
20. Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM, Hirano I. Elimination Diet Effectively Treats Eosinophilic Esophagitis in Adults; Food Reinroduction Identifies Causative Factors. Gastroenterology 2012; 142: 1451-9.e1
21. Spiegel JM, Brown-Whitehorn TF, Cianferoni A, Shaker M, Wang ML, Verma R, Liacouras CA. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol 2012; 130: 461-467.e8
22. Pentik S, Putnam PE, Collins MH, Rothenberg ME. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009;48:152-60.
23. DeBrosse CW, Franciosi JP, King EC, Butz BK, Greenberg AB, Collins MH, Abonia JP, Assa’aad A, Putnam PE, Rothenberg ME. Long-term outcomes in pediatric-onset esophageal eosinophila. J Allergy Clin Immunol 2011; 128: 132-138
24. Straumann A, Hoesli S, Bussmann C, Stuck M, Perkins M, Collins LP, Payton M, Pettipher R, Hunter M, Steiner J, Simon HU. Anti-eosinophilic activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013; 68: 375-385
25. Assa’aad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Pershey TL, Jurgenzen CH, Ortega HG, Avees SS. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011; 141: 1593-1604
26. Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, Shaheen NJ, Dellon ES. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients. Clin Gastroenterol Hepatol 2015; 13: 452-458
27. Dellon ES, Kim HP, Sperry SL, Rybnicek DA, Woosley JT, Sha-
A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. *Gastrointest Endosc* 2014; 79: 577-85.e4

28 Schoepfer AM, Safroneeva E, Bussmann C, Kuchen T, Portmann S, Simon HU, Straumann A. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. *Gastroenterology* 2013; 145: 1230-1236 e2

29 Franciosi JP, Hommel KA, Debrosse CW, Greenberg AB, Greenler AJ, Abonia JP, Rothenberg ME, Varni JW. Development of a validated patient-reported symptom metric for pediatric Eosinophilic Esophagitis: qualitative methods. *BMC Gastroenterol* 2011; 11: 126

30 Dellon ES, Speck O, Woodward K, Covey S, Rusin S, Shaheen NJ, Woosley JT. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. *Mod Pathol* 2015; 28: 383-390

**Peer reviewer**: Luis Rodrigo, Professor, Gastroenterology Department, University Hospital Central of Asturias, c/ Celesitno Villamil s. nº, 33.006. Oviedo. Spain.